Connection

Mitzi Nagarkatti to Ligands

This is a "connection" page, showing publications Mitzi Nagarkatti has written about Ligands.
Connection Strength

1.511
  1. Comparative analysis of interactions between aryl hydrocarbon receptor ligand binding domain with its ligands: a computational study. BMC Struct Biol. 2018 12 06; 18(1):15.
    View in: PubMed
    Score: 0.565
  2. AhR Activation Leads to Attenuation of Murine Autoimmune Hepatitis: Single-Cell RNA-Seq Analysis Reveals Unique Immune Cell Phenotypes and Gene Expression Changes in the Liver. Front Immunol. 2022; 13:899609.
    View in: PubMed
    Score: 0.180
  3. Computational prediction and in vitro validation of VEGFR1 as a novel protein target for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Sci Rep. 2019 05 02; 9(1):6810.
    View in: PubMed
    Score: 0.145
  4. Dietary Indoles Suppress Delayed-Type Hypersensitivity by Inducing a Switch from Proinflammatory Th17 Cells to Anti-Inflammatory Regulatory T Cells through Regulation of MicroRNA. J Immunol. 2016 Feb 01; 196(3):1108-22.
    View in: PubMed
    Score: 0.115
  5. Indoles mitigate the development of experimental autoimmune encephalomyelitis by induction of reciprocal differentiation of regulatory T cells and Th17 cells. Br J Pharmacol. 2013 Jul; 169(6):1305-21.
    View in: PubMed
    Score: 0.097
  6. Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells. J Biol Chem. 2011 Jan 07; 286(1):24-34.
    View in: PubMed
    Score: 0.081
  7. Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes. J Biol Chem. 2003 Oct 31; 278(44):43818-30.
    View in: PubMed
    Score: 0.049
  8. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 2002 Jul 15; 100(2):627-34.
    View in: PubMed
    Score: 0.045
  9. The Ability of AhR Ligands to Attenuate Delayed Type Hypersensitivity Reaction Is Associated With Alterations in the Gut Microbiota. Front Immunol. 2021; 12:684727.
    View in: PubMed
    Score: 0.042
  10. CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death. J Immunol. 2001 May 15; 166(10):5889-97.
    View in: PubMed
    Score: 0.042
  11. AhR Ligands Differentially Regulate miRNA-132 Which Targets HMGB1 and to Control the Differentiation of Tregs and Th-17 Cells During Delayed-Type Hypersensitivity Response. Front Immunol. 2021; 12:635903.
    View in: PubMed
    Score: 0.041
  12. Role of Fas-Fas ligand interactions in 2,3,7,8-tetrachlorodibenzo- p-dioxin (TCDD)-induced immunotoxicity: increased resistance of thymocytes from Fas-deficient (lpr) and Fas ligand-defective (gld) mice to TCDD-induced toxicity. Toxicol Appl Pharmacol. 1999 Oct 15; 160(2):141-55.
    View in: PubMed
    Score: 0.038
  13. An endogenous aryl hydrocarbon receptor ligand, ITE, induces regulatory T cells and ameliorates experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2018 08 01; 315(2):G220-G230.
    View in: PubMed
    Score: 0.034
  14. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol. 2007 Mar; 122(3):259-70.
    View in: PubMed
    Score: 0.015
  15. Combined screening of thymocytes using apoptosis-specific cDNA array and promoter analysis yields novel gene targets mediating TCDD-induced toxicity. Toxicol Sci. 2004 Mar; 78(1):116-24.
    View in: PubMed
    Score: 0.013
  16. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome. J Immunol. 1998 Sep 15; 161(6):3077-86.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.